Log in
Enquire now
‌

US Patent 10562850 Human plasma kallikrein inhibitors

Patent 10562850 was granted and assigned to BioCryst Pharmaceuticals on February, 2020 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals
Current Assignee
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10562850
Patent Inventor Names
Yarlagadda S. Babu0
Pravin L. Kotian0
V. Satish Kumar0
Weihe Zhang0
Lakshminarayana Vogeti0
Date of Patent
February 18, 2020
Patent Application Number
15764071
Date Filed
September 30, 2016
Patent Citations Received
‌
US Patent 11066360 Human plasma kallikrein inhibitors
Patent Primary Examiner
‌
Charanjit Aulakh
Patent abstract

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10562850 Human plasma kallikrein inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us